The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review - Scorecard - MDSpire

The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review

Sexual dysfunction is a lasting effect of treatment and can impact the quality of life of breast cancer survivors. This review examined the impact of different levels (none/low, moderate, and high) of physical activity on sexual outcomes in breast cancer survivors.

  • By

  • Mary Sou

  • Ashley Martinez

  • Joyce Dains

  • May 13, 2026

  • 25 min

Share

Clinical Scorecard: The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationBreast cancer survivors (BCSs), particularly cisgender women and other gender identities.
Care Setting

Key Highlights

  • source_clarity

Guideline-Based Recommendations

Diagnosis

    Management

    • Encourage physical activity as part of holistic care for BCSs, including specific activities like walking, yoga, and strength training.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Hormonal treatments can lead to sexual dysfunction; physical activity, such as aerobic exercises and strength training, may mitigate some effects.

        Clinical Best Practices

        • Incorporate discussions about sexual health into routine care for BCSs, and provide training for healthcare providers on this topic.

        Related Resources & Content

        Original Source(s)

        The Impact of Physical Activity Levels on Sexual Function in Breast Cancer Survivors: An Integrative Review

        • by Mary Sou, Ashley Martinez, Joyce Dains

        • May 13, 2026

        Related Content

        Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

        From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

        Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy